This systematic bibliometric analysis of 2,576 documents (2,072 research articles and 504 reviews) from the Web of Science Core Collection, validated with PubMed, examines the landscape of multi-omics research in systemic autoimmune rheumatic diseases. The analysis quantifies publication trends, geographic contributions, and thematic evolution over time.
Annual publication output increased from 11 in 2005 to 525 by 2025. Geographic distribution shows China contributing 27% and the United States 17.3% of the literature, with European countries demonstrating high collaboration rates (MCP up to 39.2%). Thematic analysis indicates an evolution from proteomics and synovial fluid profiling to epigenetics and metabolomics, and more recently toward single-cell RNA sequencing-driven immune cell differentiation research.
The authors note that this analysis is limited to Web of Science Core Collection data and does not include primary clinical data, effect sizes from trials, or safety outcomes. It reports associations and trends, not causal relationships.
Practice relevance is confined to providing a quantitative framework for evaluating the current maturity and future translational direction of multi-omics research in autoimmune diseases. It does not inform clinical decision-making regarding specific interventions.
View Original Abstract ↓
BackgroundMulti-omics technologies have increasingly been applied to systemic autoimmune rheumatic diseases (SARDs), yet the global research landscape and thematic evolution of this field remain unclear.ObjectiveThis study intends to systematically review the application status and development trends of multi-omics technologies in SARDs research over the past two decades via bibliometric analysis, so as to guide future research directions.MethodsRelevant English literatures on multi-omics application in SARDs were retrieved from the Web of Science Core Collection (WoSCC) database, covering the period from January 1, 2005, to Dec 31, 2025. Multi-omics was operationally defined as studies reporting integration of at least two omics layers in one investigation. After deduplication and visual screening, A total of 2576 documents (2072 research articles and 504 reviews) were included. Bibliometric and visual analyses were performed using CiteSpace, VOSviewer, Phthon and bibliometrix. R package.A complementary PubMed analysis was performed to validate thematic robustness and assess clinically oriented studies.ResultsAnnual output increased from 11 publications in 2005 to 525 by 2025, with three developmental phases: exploratory (2005–2015), acceleration (2016–2020), and expansion (2021–2025). China (27%) and the United States (17.3%) accounting for 44.3% of total output. European countries demonstrated higher international collaboration rates (MCP% up to 39.2%). Core institutions included Harvard University and the University of California et al. Keyword and burst analyses indicated a thematic shift from proteomics and synovial fluid profiling to epigenetics and metabolomics, and most recently to single-cell RNA sequencing–driven immune cell differentiation research. Citation analysis revealed a centralized intellectual structure anchored in high-impact immunology and rheumatology journals. PubMed validation confirmed consistent growth patterns and thematic concentration on biomarker discovery and mechanistic studies.ConclusionMulti-omics research in SARDs has progressed from bulk molecular characterization toward high-resolution immune cell–level investigation, with increasing emphasis on biomarker stratification and immune heterogeneity. By delineating developmental phases, global collaboration patterns, and thematic immunological shifts, this study provides a quantitative framework for evaluating the current maturity and future translational direction of multi-omics research in autoimmune diseases.